¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"arginine dihydrolase pathway"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • sensory pathway
    °¨°¢·Î
  • ubiquitin-protease pathway
    À¯ºñÄûƾ´Ü¹éºÐÇØÈ¿¼ÒÅë·Î
  • visual pathway
    ½Ã°¢°æ·Î
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • proximal common pathway
    ±ÙÀ§°øÅë°æ·Î.
  • pyruvate pathway
    ÇÇ·çºê»ê¿°´ë»ç°æ·Î(¡­ß«ç¤ÓÛÞóÌèÖØ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • complement system, classic pathway
    ÀüÇüÀû °æ·Î(îðúþîÜÌèÖØ)
  • corticastriatal pathway
    ÇÇÁú¼±Á¶Ã¼°æ·Î(ù«òõàÊðÉô÷ÌèÖØ)
  • cyclooxygenase pathway
    »çÀÌŬ·Î¿Á½Ã°Ô³ªÁ¦ ȸ·Î(¡­üÞÖØ)
  • direct oxidative pathway
    Á÷Á¢»êÈ­°æ·Î.
  • dopaminergic pathway
    µµÆÄ¹Î °æ·Î
  • extrinsic pathway
    ¿ÜÀμº °æ·Î.
  • extrinsic pathway
    ¿ÜÀμº °æ·Î(ÌèÖØ)
  • final common pathway
    ÃÖÁ¾°øÅë°æ·Î.
  • glucuronic acid pathway
    ±Û·çÄí·Ð»ê°æ·Î.
  • glycolytic pathway
    ÇØ´ç°æ·Î
  • intrinsic pathway
    ³»Àμº °æ·Î(Ò®ì×àõÌèÖØ).
  • lipoxygenase pathway
    Áö¹æ»êÈ­È¿¼Ò°æ·Î(¡­ß«ûùý£áÈÌèÖØ)
  • mesolimbic-mesocortical pathway
    Áߺ¯¿¬°è-ÁßÇÇÁú°æ·Î(ñéÜ«æÞÍ£-ñéù«òõÌèÖØ)
  • metabolic pathway
    ´ë»ç°æ·Î.
  • neurohumoral pathway
    ½Å°æ¾×¼º °æ·Î(~ÌèÖØ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ED pathway
    ED °æ·Î(ÌèÖØ)
  • Embden-Meyerhof pathway
    ¿¥µ§-¸¶À̾îÈ£ÇÁ °æ·Î(ÌèÖØ)
  • Entner-Doudoroff pathway
    ¿£Æ®³Ê-µÎµµ·ÎÇÁ °æ·Î(ÌèÖØ)
  • extrinsic pathway
    ¿ÜÀÎ °æ·Î (èâì×ÌèÖØ)
  • feeder pathway
    °ø±Þ °æ·Î (ÍêÐåÌèÖØ)
  • fumarate pathway
    Ç»¸¶¸£»ê(ß«) °æ·Î(ÌèÖØ)
  • glucuronate pathway
    ±Û·çÅ¥·Ð»ê(ß«) °æ·Î(ÌèÖØ)
  • glucuronic acid oxidation pathway
    ±Û·çÅ¥·Ð»ê(ß«) »êÈ­°æ·Î(ß«ûùÌèÖØ)
  • glycerate pathway
    ±Û¸®¼¼¸£»ê(ß«) °æ·Î(ÌèÖØ)
  • glycolytic pathway
    ´çºÐÇØ °æ·Î(ÓØÝÂú°ÌèÖØ)
  • hexose diphosphate pathway
    ÀÌÀλê(ì£×òß«) Çí¼Ò½º °æ·Î (ÌèÖØ)
  • hexose monophosphate oxidative pathway
    ÀÏÀλê(ìé×òß«) Çí¼Ò½º »êÈ­°æ·Î (ß«ûùÌèÖØ)
  • hexose monophosphate pathway
    ÀÏÀλê(ìé×òß«) Çí¼Ò½º °æ·Î(ÌèÖØ)
  • hoxose phosphoketolase pathway
    Çí¼Ò½º Æ÷½ºÆ÷ŰÅç·¹À̽º °æ·Î(ÌèÖØ)
  • intrinsic pathway
    ³»ÀÎ °æ·Î(Ò®ì×ÌèÖØ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AVP   1) Active non apeptide(?)
  2) Arginine Vaso-Pressin
AVT Arginine Vaso-Tocin
DDAVP 1-Desamino-8-D-Arginine Vasopressin
  = Desmopression
AHU acute hemolytic uremic [syndrome]; arginine, hypoxanthine, and uracil
AITT arginine insulin tolerance test; augmented insulin tolerance test
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EPI Extrinsic Pathway Inhibitor
HMP Hexose monophosphate pathway
rTFPI Recombinant tissue factor pathway inhibitor
TFPI TF pathway inhibitor
TFPI Tissue Factor Pathway Inhibitor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • descending pathway
    ÇÏÇà °æ·Î
  • dorsal column pathway
    ¹è ôÁÖ °æ·Î
    Ã˰¢ÀÇ A
  • efferent neural pathway
    ¿ø½É¼º ½Å°æ·Î
    ÁßÃ߽Űæ°è·ÎºÎÅÍ Àü´ÞµÇ¾î ³ª°¡´Â ½Å°æ ÀÓÆÞ½º.
  • humoral pathway
    ü¾× Åë·Î
  • intrinsic pathway
    ³»ºÎ °æ·Î, ³»Àμº °æ·Î
  • medial pathway
    ³»Ãø °æ·Î
  • meridian pathway
    °æ¶ô, °æ·Î
    µ¿¾ç ÀÇÇп¡¼­ ¹°¸® ¿ä¹ý, ƯÈ÷ ħ±¸ Ä¡·áÀÇ À̷Рü°è·Î¼­ Áß¿ä½ÃµÇ´Â °æÇ÷
  • metabolic pathway
    ´ë»ç °æ·Î
  • neural pathway
    ½Å°æ °æ·Î, ½Å°æ Åë·Î
    ÀÓÆÞ½º°¡ Àü´ÞµÇ´Â ½Å°æ ±¸Á¶¹°.
  • orbiting pathway
    ±Ëµµ
  • paleothalamic pathway
    °í½Ã»ó Àü´Þ·Î
  • paramedian pathway
    Á¤Áß¹æ °æ·Î
  • pathway
    °æ·Î, Àüµµ·Î
    Àüµµ·Î¶ó°í ÇÏ´Â °ÍÀº ³ú ¶Ç´Â ô¼ö¿¡ À־ÀÇ ÁßÃß¿Í ½Åü ¸»Ãʸ¦ ¿¬°áÇÏ´Â Åõ»ç ½Å°æ·Î¸¦ ¸»ÇÏ´Â °ÍÀ¸·Î Åõ»ç ½Å°æ·Î´Â ½Ä¹° ½Å°æ°è¿¡ ¼ÓÇÏ´Â °Í°ú µ¿¹° ½Å°æ°è¿¡ ¼ÓÇÏ´Â °ÍÀ¸·Î ´ëº°ÇÒ ¼ö ÀÖ´Ù. ±×ÀÇ ¾î´À °Í¿¡µµ »óÇ༺
  • pentose hosphate pathway

    pentose nucleic acid (ÆæÅ佺 ÇÙ»ê

  • salvage pathway
    ±¸Á¦ °æ·Î, ÀçÀÌ¿ë °æ·Î
    ±âÁ¸ ¹°ÁúÀ» »ç¿ëÇØ ÇÕ¼ºÇÏ´Â °æ·Î.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
arginine-trna ligase <enzyme> An enzyme that activates arginine with its specific transfer RNA.
Chemical name: L-Arginine:tRNA(Arg)ligase (AMP-forming)
Registry number: EC 6.1.1.19
(12 Dec 1998)
arginine vasopressin [8-arginine]vasopressin; [Arg8]vasopressin;vasopressin containing an arginyl residue in position 8 (as in chickens and most mammals, including man); porcine vasopressin has a lysyl residue at position 8. All are vasopressors.
Synonym: argipressin.
(05 Mar 2000)
arginine vasotocin Vasotocin with arginyl residue at position 8 (identical with arginine oxytocin).
See: arginine vasopressin.
(05 Mar 2000)
beta-alanyl-arginine hydrolase <enzyme> Also hydrolyzes carnosine, at a lower rate; requires mn2+; inhibited by bestatin; stabilised by sulfhydryl reagents
Registry number: EC 3.4.13.-
Synonym: ala-arg hydrolase
(26 Jun 1999)
calcium-calmodulin-activated histone 3 arginine kinase <enzyme> From nuclear extracts of dividing and quiescent rat heart endothelial cells; represents a new class of ca-cam-dependent kinases which phosphorylate arg
Registry number: EC 2.7.10.-
Synonym: ca(2+)-calmodulin-activated histone 3 arg kinase, ca-cam h3 kinase
(26 Jun 1999)
complement 5a, des-arginine Complement 5a with the carboxy-terminal arginine removed. The arginine is rapidly cleaved from the c5a fragment during complement activation by carboxypeptidase b present in normal human serum. C5a des-arg shows complete loss of spasmogenic activity though it retains some chemotactic ability.
(12 Dec 1998)
protein-arginine n-methyltransferase <enzyme> An enzyme that catalyses the methylation of arginine residues of proteins to yield n-mono- and n,n-dimethylarginine. This enzyme is found in many organs, primarily brain and spleen.
Chemical name: S-Adenosyl-L-methionine:protein-L-arginine N-methyltransferase
Registry number: EC 2.1.1.23
(12 Dec 1998)
NAD(p)-arginine ADP-ribosyltransferase <enzyme> An enzyme that catalyses the transfer of the ADP-ribose moiety from NAD to specific protein substrates with agmatine, arginine-type compounds, or guanidine as acceptors. This reaction can be catalyzed by prokaryotic and eukaryotic enzyme systems. Mono-ADP-ribosylation is a mechanism of action common to several bacterial toxins. It effects profound changes in cellular metabolism, such as activation of adenylate cyclase, regulation of protein synthesis at the level of elongation factor 2, and ion transport across biological membranes.
Chemical name: NAD(+)-L-arginine ADP-D-ribosyltransferase
Registry number: EC 2.4.2.31
(12 Dec 1998)
N-arginine dibasic convertase <enzyme> Catalyses cleavage at the n-terminus of arginine residues in dibasic stretches of proteins; located in brain cortex; genbank l27124
Registry number: EC 3.4.24.-
Synonym: nrd convertase, n-arg dibasic convertase
(26 Jun 1999)
alternative oxidase pathway Pathway of mitochondrial electron transport in higher plants, particularly in fruits and seeds, that does not involve cytochrome oxidase and thus is resistant to cyanide.
(18 Nov 1997)
alternative pathway See: complement activation.
(18 Nov 1997)
anabolic pathway <biochemistry> A reaction or series of reactions in a metabolic pathway that synthesise complex molecules from simpler ones, usually requiring the input of energy.
Compare: catabolic pathway.
(09 Oct 1997)
auditory pathway Neural paths and connections within the central nervous system, beginning at the organ of Corti's hair cells, continuing along the eighth nerve, and terminating at the auditory cortex.
(05 Mar 2000)
GABA pathway The pathway that ultimately converts 4-aminobutyrate to succinate; succinate is then converted to alpha-ketoglutarate, via the tricarboxylic acid cycle, which is then acted upon by glutamate dehydrogenase; glutamate is then decarboxylated to reform 4-aminobutyrate; an important pathway for those cells which make this neuroactive molecule.
Synonym: GABA pathway.
(05 Mar 2000)
Palade pathway <cell biology> The routing of proteins from the site of their synthesis to the final cellular or secreted position. Several different pathways are known and others suspected. Glycosylation of the proteins may provide specific address labels for the proteins.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á